Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ventyx Biosciences ( (VTYX) ) has shared an announcement.
Ventyx Biosciences held its Annual Meeting of Stockholders on June 4, 2025, where approximately 70% of the outstanding shares were represented. During the meeting, two Class I directors, Somasundaram Subramaniam and Sheila Gujrathi, were re-elected to serve until 2028. Additionally, the executive compensation proposal was approved, and the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025 was ratified.
The most recent analyst rating on (VTYX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Ventyx Biosciences stock, see the VTYX Stock Forecast page.
Spark’s Take on VTYX Stock
According to Spark, TipRanks’ AI Analyst, VTYX is a Neutral.
Ventyx Biosciences’ overall score reflects the challenges typical of a pre-revenue biotech firm, with significant financial risks due to lack of revenue and negative equity. While the company has strong liquidity, it relies heavily on external funding. The technical analysis suggests a bearish trend, and valuation metrics indicate ongoing losses, contributing to a low overall score.
To see Spark’s full report on VTYX stock, click here.
More about Ventyx Biosciences
Average Trading Volume: 1,353,386
Technical Sentiment Signal: Hold
Current Market Cap: $175.1M
For detailed information about VTYX stock, go to TipRanks’ Stock Analysis page.